CHEK1 and glioblastoma: RRM2 is a promising therapeutic target for glioblastoma, and the use of triapine can effectively target RRM2, making glioblastoma cells more sensitive to radiation and inducing synthetic lethality when combined with checkpoint kinase 1 inhibition.10